Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses J Zhou, X Ma, T Wang, S Zhai Osteoporosis International 27, 3289-3300, 2016 | 86 | 2016 |
Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update R Han, J Zhou, C François, M Toumi BMC infectious diseases 19, 1-14, 2019 | 72 | 2019 |
Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials TT Qiu, C Zhang, HW Zhao, JW Zhou Autoimmunity Reviews 16 (2), 136-145, 2017 | 57 | 2017 |
Acid‐suppressive drugs and risk of kidney disease: a systematic review and meta‐analysis T Qiu, J Zhou, C Zhang Journal of gastroenterology and hepatology 33 (9), 1566-1573, 2018 | 33 | 2018 |
Adverse effects of incretin‐based therapies on major cardiovascular and arrhythmia events: meta‐analysis of randomized trials T Wang, F Wang, J Zhou, H Tang, S Giovenale Diabetes/metabolism research and reviews 32 (8), 843-857, 2016 | 33 | 2016 |
Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-analyses J Zhou, T Wang, X Zhao, DR Miller, S Zhai Rheumatology and therapy 3, 117-128, 2016 | 28 | 2016 |
Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study E Clay, J Zhou, ZM Yi, S Zhai, M Toumi Journal of market access & health policy 7 (1), 1667195, 2019 | 27 | 2019 |
Systematic review of pharmacoeconomic models for schizophrenia J Zhou, A Millier, M Toumi Journal of market access & health policy 6 (1), 1508272, 2018 | 16 | 2018 |
Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian countries Y Wang, T Qiu, J Zhou, C Francois, M Toumi Applied Health Economics and Health Policy 19, 281-304, 2021 | 15 | 2021 |
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results J Zhou, A Millier, C François, S Aballéa, M Toumi Journal of market access & health policy 7 (1), 1648973, 2019 | 14 | 2019 |
双膦酸盐类抗骨质疏松治疗的相对有效性及安全性评估 周俊文, 马翔, 翟所迪 中国临床药理学杂志 31 (12), 1197-1201, 2015 | 10 | 2015 |
Incorporating future unrelated medical costs in cost-effectiveness analysis in China S Jiang, Y Wang, J Zhou, Y Jiang, GG Liu, J Wu BMJ Global Health 6 (10), e006655, 2021 | 9 | 2021 |
Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis K Wang, ZH Liu, XY Li, YF Li, JR Li, JJ Hui, JX Li, JW Zhou, ZM Yi Frontiers in Aging Neuroscience 15, 1134472, 2023 | 7 | 2023 |
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK J Zhou, R Wu, C Williams, J Emberson, C Reith, A Keech, J Robson, ... Pharmacoeconomics 41 (5), 547-559, 2023 | 6 | 2023 |
Evaluation of rivaroxaban-, apixaban-and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database M Guo, S Thai, J Zhou, J Wei, Y Zhao, W Xu, T Wang, X Cui International Journal of Clinical Pharmacy 43 (6), 1508-1515, 2021 | 6 | 2021 |
A systematic review of the factors associated with suicide attempts among sexual-minority youth XX Wang, Q Gan, J Zhou, M Cosquer, B Falissard, E Corruble, ... The European Journal of Psychiatry 37 (2), 72-83, 2023 | 4 | 2023 |
Oncology from an HTA and health economic perspective C Francois, J Zhou, M Pochopien, L Achour, M Toumi Regulatory and Economic Aspects in Oncology, 25-38, 2019 | 4 | 2019 |
Advanced therapy medicinal products for Alzheimer's Disease will shrink the National Health Service budget E Hanna, J Zhou, X Cheng, J Dorey, S Aballéa, P Auquier, M Toumi Value in Health 19 (7), A523, 2016 | 2 | 2016 |
碳酸镧在非透析慢性肾脏病患者中的有效性和安全性的系统评价 门鹏, 唐惠林, 周俊文, 翟所迪 中国新药杂志 25 (2), 193-197, 2016 | 2 | 2016 |
药师在老年科临床药学实践的系统评价 闫盈盈, 周俊文, 翟所迪 中国医院药学杂志 35 (16), 1496-1502, 2015 | 2 | 2015 |